May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Boston Ocular Surface Prosthesis Improves Visual Function in Patients With Ocular Surface Disease From Chronic Graft-Versus-Host Disease
Author Affiliations & Notes
  • D. S. Jacobs
    Boston Foundation for Sight, Needham, Massachusetts
    Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • P. Rosenthal
    Boston Foundation for Sight, Needham, Massachusetts
    Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  D.S. Jacobs, None; P. Rosenthal, None.
  • Footnotes
    Support  Drs. Jacobs and Rosenthal are salaried employees of the not-for-profit 501(c)3 Boston Foundation for Sight
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2362. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. S. Jacobs, P. Rosenthal; Boston Ocular Surface Prosthesis Improves Visual Function in Patients With Ocular Surface Disease From Chronic Graft-Versus-Host Disease. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2362. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the impact of wearing the Boston Ocular Surface Prosthesis (BOSP) on visual function in patients with ocular surface disease related to chronic graft-versus-host disease (cGvHD).

Methods: : All patients referred to this institution for consideration of treatment with the BOSP (formerly known as Boston Scleral Lens) from January through June 2006 were administered the NEI VFQ-25 at entry, and again 6 months later. Our patient database was sorted by diagnosis identifying the cGvHD subgroup (n=16) in this cohort. The characteristics of this subgroup were extracted by data base analysis and retrospective chart review. This subgroup consists of 12 males and 14 females of ages 28 - 63 years (mean = 49). Underlying malignancy, type of transplant, and prior conventional ophthalmic therapy was tabulated and is reported. Baseline composite NEI VFQ-25 scores and self-reported general health status scores in this subgroup and scores at 6 month follow-up are reported, along with mean change in score. Scores are reported on scale 0 - 100, with 100 = highest level of function. The unpaired t-test was used to compare baseline composite scores of patients fitted vs. not fitted. The paired t-test was used to evaluate change in composite and self-reported general health score in those fitted.

Results: : Mean baseline composite score on the NEI VFQ-25 was 62 (range 35-91, n=16). Of these 16 patients, 13 were fitted with the BOSP. Mean score for patients not fitted was 74 (n=3), whereas mean score for patients fitted was 59 (n=13), (P = 0.20, unpaired t-test ). NEI VFQ-25 scores of patients fitted and who had 6 month followup data (n=12), had mean = 57 (S.E = 5.06) at baseline and mean = 77 (S.E. = 5.52) at 6 months, with mean change in score = +20, (P <0.0003, paired t-test). Self-reported general health status was not significantly different at baseline (mean = 60) and 6 months (mean = 56, P=0.6147, paired t-test), in this group of patients. No patient categorized his or her general health as poor.

Conclusions: : The BOSP significantly improves visual function in patients with ocular surface disease, unresponsive to conventional therapy, from cGvHD, in a sample that includes patients of both sexes, and a broad range of ages, underlying malignancies, and self-reported general health states. There was no concurrent improvement in general health status in this subgroup to explain this finding.

Keywords: cornea: clinical science • contact lens • quality of life 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×